Jean-Luc Cracowski

institut national de la santé et de la recherche médicale (inserm)

H指数:51

被引数:8,799

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Endothelial Cell Senescence and Mitochondrial Dysfunction in Vascular Ageing

内皮细胞衰老和线粒体功能障碍在血管衰老中的作用

Ageing Research Reviews

IF12.4

2026-04-020

OAAI

Assessing the risk-benefit balance of medicines: Some lessons from Covid-19

评估药物的风险-效益平衡：来自Covid-19的一些启示

M S-MEDECINE SCIENCES

IF0.4

2026-03-200

PRE

Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge

阿托伐他汀相关肝损伤：再次使用他汀类药物后的转归

FUNDAMENTAL & CLINICAL PHARMACOLOGY

IF2.5

2026-03-010

PRE

Treprostinil Iontophoresis in Diabetic Foot Ulcers: A Single Ascending Dose Safety Study

曲前列素离子导入治疗糖尿病足溃疡：一项单次递增剂量安全性研究

FUNDAMENTAL & CLINICAL PHARMACOLOGY

IF2.5

2025-12-010

OAAI

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database

药物诱导的雷诺现象及其潜在机制：一项来自WHO药物警戒数据库的不均衡性分析

Arthritis & Rheumatology

IF10.9

2025-11-190

OAAI

Validation of in-hospital diagnosis codes in one French hospital and out-hospital algorithm to identify skin ulcers in healthcare databases in France

THERAPIE

IF1.8

2025-10-010

OAAI

Sotatercept in pulmonary arterial hypertension

sotatercept 在肺动脉高压中的应用

Trends in Pharmacological Sciences

IF19.9

2025-05-160

PRE

Trial-level surrogacy of non-high-density and low-density lipoprotein cholesterol reduction on the clinical efficacy of statins

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY

IF6.1

2025-02-250

PRE

Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study

DRUG SAFETY

IF3.8

2025-02-220

OAAI

Signal detection of drugs associated with obstructive and central sleep apnoea

SLEEP MEDICINE

IF3.4

2024-12-010

OAAI

Characteristics and outcomes of gemcitabine-associated pulmonary hypertension

吉西他滨相关性肺动脉高压的特点和预后

EUROPEAN RESPIRATORY JOURNAL

IF21

2024-10-300

Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data

DIABETES CARE

IF16.6

2024-08-270

Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-06-191

PRE

Exploring the feelings of being at risk of vaccine related adverse effects: A cross-sectional survey in France

JOURNAL OF PSYCHOSOMATIC RESEARCH

IF3.3

2023-09-013

PRE

Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database

DRUG SAFETY

IF3.8

2023-08-022

PRE

Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database

BIODRUGS

IF6.9

2023-06-062

PRE

Validity, relevance and interpretation of pharmacovigilance disproportionality analyses

BONE

IF3.6

2023-05-013

PRE

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis

识别与肺动脉高压相关的新药: WHO药物警戒数据库比例度分析

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-07-1016

OAAI

Tolerance of Fentanyl Pectin Nasal Spray for Procedural Pain in Geriatric Patients

JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION

IF3.8

2022-06-010

OAAI

Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2022-05-0110

OAAI

Jean-Luc Cracowski

个人简介

教育背景

工作经历

荣誉奖项

研究方向